JP2022507294A5 - - Google Patents
Info
- Publication number
- JP2022507294A5 JP2022507294A5 JP2021525787A JP2021525787A JP2022507294A5 JP 2022507294 A5 JP2022507294 A5 JP 2022507294A5 JP 2021525787 A JP2021525787 A JP 2021525787A JP 2021525787 A JP2021525787 A JP 2021525787A JP 2022507294 A5 JP2022507294 A5 JP 2022507294A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- pharmaceutical composition
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758442P | 2018-11-09 | 2018-11-09 | |
| US62/758,442 | 2018-11-09 | ||
| PCT/US2019/060276 WO2020097336A1 (en) | 2018-11-09 | 2019-11-07 | Cdcp1-targeted therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507294A JP2022507294A (ja) | 2022-01-18 |
| JP2022507294A5 true JP2022507294A5 (https=) | 2022-10-27 |
| JP7440509B2 JP7440509B2 (ja) | 2024-02-28 |
Family
ID=70612233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525787A Active JP7440509B2 (ja) | 2018-11-09 | 2019-11-07 | Ｃｄｃｐ１－標的化療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12371507B2 (https=) |
| EP (1) | EP3876988A4 (https=) |
| JP (1) | JP7440509B2 (https=) |
| CN (1) | CN113382750B (https=) |
| AU (1) | AU2019376078B2 (https=) |
| CA (1) | CA3118542A1 (https=) |
| MX (1) | MX2021005377A (https=) |
| WO (1) | WO2020097336A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102225039B1 (ko) * | 2018-12-17 | 2021-03-10 | 한국과학기술원 | Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물 |
| JP7623705B2 (ja) * | 2019-12-27 | 2025-01-29 | 株式会社カイオム・バイオサイエンス | 抗ｃｄｃｐ１抗体 |
| WO2023134715A1 (zh) * | 2022-01-12 | 2023-07-20 | 中国医学科学院阜外医院 | 心肌细胞的分离试剂和分离方法 |
| CA3259098A1 (en) * | 2022-06-20 | 2025-04-18 | Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. | ANTIBODIES AND THEIR USES |
| CA3261603A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | ANTIBODY-DRUG CONJUGATES |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
| WO2025226017A1 (ko) * | 2024-04-22 | 2025-10-30 | 주식회사 노벨티노빌리티 | 신규 항-cdcp1 인간화 항체 및 이의 용도 |
| WO2025252137A1 (zh) * | 2024-06-06 | 2025-12-11 | 荣昌生物制药(烟台)股份有限公司 | 一种抗体药物偶联物 |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2026078443A1 (en) | 2024-10-11 | 2026-04-16 | Pheon Therapeutics Ltd. | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU2003207459A1 (en) | 2002-01-03 | 2003-07-24 | The Scripps Research Institute | Cancer-associated epitope |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| WO2007005502A2 (en) | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
| PT2594590E (pt) * | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| US7951370B2 (en) | 2008-03-12 | 2011-05-31 | Imclone Llc | Anti-TYRP1 antibodies |
| TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗ｃｄｃｐ１抗體 |
| TW201113037A (en) * | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US9127056B2 (en) | 2011-10-17 | 2015-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) |
| PT3134127T (pt) | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| KR20170075778A (ko) | 2014-10-27 | 2017-07-03 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 항-tim-3 항체 |
| RU2757314C2 (ru) | 2016-01-22 | 2021-10-13 | Мерк Шарп И Доум Корп. | Антитела против фактора свертывания xi |
| EP3554544A4 (en) * | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
-
2019
- 2019-11-07 US US17/292,257 patent/US12371507B2/en active Active
- 2019-11-07 AU AU2019376078A patent/AU2019376078B2/en active Active
- 2019-11-07 CA CA3118542A patent/CA3118542A1/en active Pending
- 2019-11-07 CN CN201980084226.5A patent/CN113382750B/zh active Active
- 2019-11-07 JP JP2021525787A patent/JP7440509B2/ja active Active
- 2019-11-07 EP EP19883243.8A patent/EP3876988A4/en active Pending
- 2019-11-07 WO PCT/US2019/060276 patent/WO2020097336A1/en not_active Ceased
- 2019-11-07 MX MX2021005377A patent/MX2021005377A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507294A5 (https=) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| TWI755791B (zh) | 用於治療癌症之pd-1 / pd-l1抑制劑 | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| AU2024227446A1 (en) | ROR1 antibody immunoconjugates | |
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| US11718671B2 (en) | Bispecific antibody and uses thereof | |
| TW201800108A (zh) | 用於癌症治療的pd-1/pd-l1抑制劑 | |
| TWI885529B (zh) | 抗體-藥物結合物之用途 | |
| TR201901507T4 (tr) | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. | |
| US20150148585A1 (en) | Combination therapy for the treatment of glioblastoma | |
| KR20190018400A (ko) | EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체 | |
| EP2825558A2 (en) | Combination therapy for the treatment of ovarian cancer | |
| KR20240163751A (ko) | Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법 | |
| JPWO2021182570A5 (https=) | ||
| JPWO2021182571A5 (https=) | ||
| JP2025503584A (ja) | 細胞内取り込みペプチド－治療ペイロード組成物及び使用方法 | |
| JPWO2021182572A5 (https=) | ||
| Bege et al. | New anticancer medicines approved by the EMA in 2024 | |
| CA3287886A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and hif-2a inhibitor | |
| TW202400140A (zh) | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 | |
| CN120916791A (zh) | 抗CDH6抗体-药物缀合物与HIF-2α抑制剂的组合 | |
| CA3285996A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor | |
| WO2026050587A1 (en) | Novel anti-nectin-4 antibodies, conjugated biological molecules, pharmaceutical compositions and uses thereof |